London · Delayed Price · Currency is GBP · Price in GBX Theracryf Statistics
Total Valuation
Theracryf has a market cap or net worth of GBP 4.66 million. The enterprise value is 3.13 million.
| Market Cap | 4.66M |
| Enterprise Value | 3.13M |
Important Dates
The last earnings date was Monday, September 28, 2026.
| Earnings Date | Sep 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Theracryf has 2.73 billion shares outstanding. The number of shares has increased by 298.90% in one year.
| Current Share Class | 2.73B |
| Shares Outstanding | 2.73B |
| Shares Change (YoY) | +298.90% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 25.05% |
| Owned by Institutions (%) | 45.02% |
| Float | 1.81B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.76 |
| P/TBV Ratio | 23.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.00.
| Current Ratio | 1.36 |
| Quick Ratio | 1.30 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -81.30% and return on invested capital (ROIC) is -53.11%.
| Return on Equity (ROE) | -81.30% |
| Return on Assets (ROA) | -37.12% |
| Return on Invested Capital (ROIC) | -53.11% |
| Return on Capital Employed (ROCE) | -118.13% |
| Weighted Average Cost of Capital (WACC) | 11.72% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -392,333 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -37,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.81% in the last 52 weeks. The beta is 1.36, so Theracryf's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -18.81% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.21 |
| Relative Strength Index (RSI) | 42.07 |
| Average Volume (20 Days) | 3,657,341 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -3.69M |
| Operating Income | -3.70M |
| Pretax Income | -3.57M |
| Net Income | -3.53M |
| EBITDA | -3.69M |
| EBIT | -3.70M |
| Earnings Per Share (EPS) | -0.00 |
Balance Sheet
The company has 1.54 million in cash and 11,000 in debt, with a net cash position of 1.53 million or 0.00 per share.
| Cash & Cash Equivalents | 1.54M |
| Total Debt | 11,000 |
| Net Cash | 1.53M |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 2.72M |
| Book Value Per Share | 0.00 |
| Working Capital | 604,000 |
Cash Flow
| Operating Cash Flow | -2.66M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 9,000 |
| Net Borrowing | -7,000 |
| Free Cash Flow | -2.66M |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Theracryf does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -298.90% |
| Shareholder Yield | -298.90% |
| Earnings Yield | -73.85% |
| FCF Yield | -55.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |